What is AbbVie Inc's share price today?
AbbVie Inc (ABBV) share price today is $290.81 as of October 30, 2026 at 1:30 AM IST. The stock touched a day high of $292.31 and a day low of $288.14.What exchange does AbbVie Inc stock trade on, and under what ticker symbol?
AbbVie Inc stock trades on NYSE under the ticker symbol ABBV.What is AbbVie Inc's market capitalization?
AbbVie Inc's market capitalization is $506.08B as of October 30, 2026 at 1:30 AM IST.What is AbbVie Inc's price-to-earnings (P/E) ratio?
AbbVie Inc's price-to-earnings (P/E) ratio is 80.90 as of October 29, 2026.What is AbbVie Inc's price-to-book (P/B) ratio?
AbbVie Inc's price-to-book (P/B) ratio is 50.45 as of October 29, 2026.Does AbbVie Inc pay a dividend, and what is its dividend yield?
Yes, AbbVie Inc pays a dividend, with a current dividend yield of 2.38%.Can Indian investors buy AbbVie Inc shares?
Yes, You can buy AbbVie Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in AbbVie Inc shares from India?
Indian investors can buy AbbVie Inc shares in three steps: 1. Search AbbVie Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from AbbVie Inc shares for Indian investors?
Since AbbVie Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in AbbVie Inc shares via Tickertape?
Indian investors can start investing in AbbVie Inc (ABBV) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0343 shares at the current price of $290.81.
$
₹
$290.811.68% (+4.82)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
80.90
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
50.45
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$3.54
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
0.58
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
9.8%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
2.38%
Based on 30 analysts reports
Buy24 analysts
Hold5 analysts
Sell1 analyst
Price Upside
-0.98%
Earnings Growth
+39.54%
Rev. Growth
+10.58%
Company Profile
Company Profile
AMGN
P/E Ratio
27.82
27.82
1Y Return
55.96%
55.96%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
39.75%
39.75%
Buy Reco %
78.57
78.57
P/E Ratio
29.73
29.73
1Y Return
29.43%
29.43%
Buy Reco %
81.25
81.25
P/E Ratio
20.18
20.18
1Y Return
25.56%
25.56%
Buy Reco %
67.85
67.85
MRNA
P/E Ratio
—
—
1Y Return
801.86%
801.86%
Buy Reco %
21.73
21.73
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$285.99Baseline
Analyst Target - 1 year
Target$283.19-0.98%
All values in $
2026
Current$285.99Baseline
Analyst Target - 1 year
Target$283.19-0.98%
All values in $
Revenue Forecast
Revenue Forecast
Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies 10.58% growth, versus a trailing 3-year CAGR of 1.75%.
2025
Current$61.16Baseline
Forecast for Dec 2026
High$67.99+11.17%
Average$67.63+10.58%
Low$67.24+9.95%
All values in $ Billion
2025
Current$61.16Baseline
Forecast for Dec 2026
High$67.99+11.17%
Average$67.63+10.58%
Low$67.24+9.95%
All values in $ Billion
Earnings Per Share Forecast
Earnings Per Share Forecast
Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies 39.54% growth, versus a trailing 3-year CAGR of -10.16%.
2025
Current$10Baseline
Forecast for Dec 2026
High$14.25+42.5%
Average$13.95+39.54%
Low$13.81+38.1%
All values in $
2025
Current$10Baseline
Forecast for Dec 2026
High$14.25+42.5%
Average$13.95+39.54%
Low$13.81+38.1%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 12.31 | 14.46 | 14.46 | 15.10 | 13.34 | 15.42 | 15.77 | 16.61 | 15 | 16.99 |
Gross Profit | 8.21 | 10.26 | 10.24 | 10.70 | 9.34 | 11.07 | 10.47 | 12.06 | 10.78 | 12.69 |
| Net Income | 1.36 | 1.37 | 1.56 | -0.02 | 1.28 | 0.93 | 0.18 | 1.81 | 0.69 | 3.61 |
| Net Profit Margin | 11.12% | 9.47% | 10.79% | -0.14% | 9.63% | 6.08% | 1.17% | 10.92% | 4.65% | 21.26% |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareDrug Manufacturers - General
HealthcareDrug Manufacturers - General
Valuation
Returns
Forecast
Compare valuation on Screener| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| AbbVie Inc | 80.90 | 50.45 | 0.58 |
| Amgen Inc | 27.82 | 20.56 | 2.65 |
| Gilead Sciences Inc | - | 16.63 | 2.34 |
Price Comparison
Price Comparison
Compare ABBV with any stock or ETFCompare ABBV with any stock or ETF
Comparing from
ABBV
AMGN
GILD
The 12-month consensus target implies -0.98% growth, versus a trailing 3-year CAGR of 29.31%.